Tandem Diabetes Care (NASDAQ:TNDM) Raised to “Buy” at Stifel Nicolaus

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) was upgraded by investment analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research note issued on Wednesday, MarketBeat Ratings reports. The firm currently has a $26.00 price target on the medical device company’s stock, up from their prior price target of $22.00. Stifel Nicolaus‘s price objective suggests a potential upside of 54.76% from the company’s previous close.

TNDM has been the subject of a number of other research reports. Truist Financial dropped their target price on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, September 24th. Citigroup reduced their price target on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th. Oppenheimer reissued an “outperform” rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Finally, William Blair assumed coverage on shares of Tandem Diabetes Care in a report on Friday, August 21st. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.39.

View Our Latest Stock Report on Tandem Diabetes Care

Tandem Diabetes Care Stock Performance

NASDAQ TNDM opened at $16.80 on Wednesday. The stock’s 50-day simple moving average is $17.24 and its two-hundred day simple moving average is $18.79. Tandem Diabetes Care has a twelve month low of $12.26 and a twelve month high of $29.65. The company has a debt-to-equity ratio of 4.47, a quick ratio of 2.65 and a current ratio of 3.20.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.15. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The firm had revenue of $283.69 million during the quarter, compared to analyst estimates of $265.85 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue was up 13.8% compared to the same quarter last year. As a group, equities research analysts predict that Tandem Diabetes Care will post -0.61 earnings per share for the current year.

Insider Transactions at Tandem Diabetes Care

In related news, Director Christopher J. Twomey sold 1,700 shares of the firm’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the transaction, the director directly owned 24,434 shares in the company, valued at $467,911.10. This trade represents a 6.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by insiders.

Institutional Trading of Tandem Diabetes Care

Several hedge funds and other institutional investors have recently bought and sold shares of TNDM. State of Tennessee Department of Treasury boosted its position in Tandem Diabetes Care by 7.2% during the 3rd quarter. State of Tennessee Department of Treasury now owns 23,652 shares of the medical device company’s stock valued at $386,000 after buying an additional 1,582 shares during the period. Public Sector Pension Investment Board grew its holdings in Tandem Diabetes Care by 0.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 237,049 shares of the medical device company’s stock worth $3,891,000 after acquiring an additional 1,591 shares during the last quarter. Sterling Capital Management LLC grew its holdings in Tandem Diabetes Care by 849.0% in the 3rd quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock worth $38,000 after acquiring an additional 2,080 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Tandem Diabetes Care in the 2nd quarter worth $33,000. Finally, HighMark Wealth Management LLC increased its position in shares of Tandem Diabetes Care by 6.4% in the third quarter. HighMark Wealth Management LLC now owns 36,320 shares of the medical device company’s stock valued at $592,000 after acquiring an additional 2,200 shares during the period.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

Further Reading

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.